摘要
目的:观察高三尖杉酯碱、小剂量阿糖胞苷以及粒细胞集落刺激因子组成的HAG预激方案在中高危骨髓增生异常综合征患者中的疗效。方法:回顾性分析我院从2008年1月至2012年2月收治的16例HAG方案化疗及12例CAG方案化疗的初诊MDS患者的临床资料。结果:HAG方案诱导缓解的有效率为87.50%(14/16),其中完全缓解率为56.25%(9/16)。CAG方案诱导缓解的有效率为91.67%(11/12),其中完全缓解率为50%(6/12)。两组之间完全缓解率及总有效率比较无统计学差异(P>0.05)。结论:HAG方案治疗中高危MDS患者安全有效,取得CR后应继续巩固强化治疗,避免早期复发。
Objective：To observe the efficacy of HAG regimen combined with homoharringtonine,low-dose cytarabine and granulocyte colony-stimulating factor on patients of intermediate and high-risk myelodysplastic syndrome.Methods：The clinical data of 16 new-diagnosed MDS cases treated with HAG regimen and 12 MDS cases treated with CAG regimen in our hospital from 2008 Jan to 2012 Feb were retrospectively analyzed.Results：The efficiency rate of HAG regimen was 87.50%（14 /16）,CR rate 56.25%（9 /16）.The efficiency rate of CAG regimen was 91.67%（11 /12） while the CR rate was 50%（6 /12）.The CR rate and RR rate between HAG and CAG regimen didn ＇t have statistically significant differences（P 0.05）.Conclusion：With acceptable adverse effect,HAG regimen is effective for the intermediate and high-risk myelodysplastic syndrome,but strong and alternative chemotherapy is necessary for CR patients to keep longer CR and survival.
出处
《现代肿瘤医学》
CAS
2013年第8期1840-1842,共3页
Journal of Modern Oncology
基金
辽宁省科学技术计划(项目编号:2010225032)
